Actively Recruiting
Autologous Tumor-Infiltrating Lymphocyte (GT307) for Treatment of Patients With Advanced Colorectal Cancer
Led by Grit Biotechnology · Updated on 2026-04-14
18
Participants Needed
1
Research Sites
151 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is a single arm, open design aimed at evaluating the safety and tolerability of Autologous Tumor-Infiltrating Lymphocyte (GT307) for treatment of patients with Advanced Colorectal Cancer,while evaluating pharmacokinetic characteristics and efficacy assessment to determine the optimal biological dose (OBD).
CONDITIONS
Official Title
Autologous Tumor-Infiltrating Lymphocyte (GT307) for Treatment of Patients With Advanced Colorectal Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Voluntarily join the study and sign informed consent
- Age 18 to 70 years old
- Advanced colorectal cancer progressing after first-line chemotherapy
- ECOG performance status score of 0 or 1
- Expected survival time of at least 12 weeks
- Good function of vital organs
- Imaging record showing disease progression before tumor sampling
- At least one measurable target lesion meeting RECIST v1.1 after tumor sampling
You will not qualify if you...
- Uncontrollable tumor-related pain or unstable analgesic regimen
- Known mental illness, alcoholism, drug use, or substance abuse
- Pregnant or lactating women, or planning pregnancy within one year after treatment
- Received other clinical trial drug treatment within 4 weeks before lymphodepletion preconditioning
- Plan to participate in other clinical trial drug treatment during the study
- Other conditions deemed unsuitable for enrollment by investigators
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Shanghai Jiaotong University School of Medcine, Renji Hospital
Shanghai, Shanghai Municipality, China
Actively Recruiting
Research Team
Z
Zheng Wang
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here